Managing immune checkpoint inhibition in transplant recipients

Lancet Oncol. 2022 Aug;23(8):969-971. doi: 10.1016/S1470-2045(22)00395-3. Epub 2022 Jul 6.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents, Immunological* / adverse effects
  • CTLA-4 Antigen
  • Humans
  • Immune Checkpoint Inhibitors
  • Transplant Recipients*

Substances

  • Antineoplastic Agents, Immunological
  • CTLA-4 Antigen
  • Immune Checkpoint Inhibitors